Phoenix Biotech Total Debt vs. Earnings Per Share
PBAXDelisted Stock | USD 10.90 0.00 0.00% |
For Phoenix Biotech profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Phoenix Biotech to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Phoenix Biotech Acquisition utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Phoenix Biotech's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Phoenix Biotech Acquisition over time as well as its relative position and ranking within its peers.
Phoenix |
Phoenix Biotech Acqu Earnings Per Share vs. Total Debt Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Phoenix Biotech's current stock value. Our valuation model uses many indicators to compare Phoenix Biotech value to that of its competitors to determine the firm's financial worth. Phoenix Biotech Acquisition is regarded fourth in total debt category among its peers. It is regarded third in earnings per share category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Phoenix Biotech's earnings, one of the primary drivers of an investment's value.Phoenix Total Debt vs. Competition
Phoenix Biotech Acquisition is regarded fourth in total debt category among its peers. Total debt of Financials industry is at this time estimated at about 12.43 Million. Phoenix Biotech holds roughly 650,000 in total debt claiming about 5% of equities under Financials industry.
Phoenix Earnings Per Share vs. Total Debt
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Phoenix Biotech |
| = | 650 K |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Phoenix Biotech |
| = | (0.35) X |
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
Phoenix Earnings Per Share Comparison
Phoenix Biotech is currently under evaluation in earnings per share category among its peers.
Phoenix Biotech Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Phoenix Biotech, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Phoenix Biotech will eventually generate negative long term returns. The profitability progress is the general direction of Phoenix Biotech's change in net profit over the period of time. It can combine multiple indicators of Phoenix Biotech, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Phoenix Biotech Acquisition Corp. does not have significant operations. The company was incorporated in 2021 and is based in Oakland, California. Phoenix Biotech is traded on NASDAQ Exchange in the United States.
Phoenix Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Phoenix Biotech. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Phoenix Biotech position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Phoenix Biotech's important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Phoenix Biotech without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Theme Ratings Now
Theme RatingsDetermine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |
All Next | Launch Module |
Use Investing Themes to Complement your Phoenix Biotech position
In addition to having Phoenix Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Furniture Thematic Idea Now
Furniture
Companies producing and selling home and office furniture. The Furniture theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Furniture Theme or any other thematic opportunities.
View All Next | Launch |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Consideration for investing in Phoenix Stock
If you are still planning to invest in Phoenix Biotech Acqu check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Phoenix Biotech's history and understand the potential risks before investing.
Global Correlations Find global opportunities by holding instruments from different markets | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |